2. Signaling Pathways
  3. Immunology/Inflammation
  4. Interleukin Related
  5. IL-33 Isoform

IL-33

IL-33 is an IL-1 family cytokine that signals through ST2/IL1RL1, activates NF-κB and MAP kinase pathways, and induces TH2-associated cytokine production[1]. Mechanistically, IL-33 links epithelial or endothelial tissue damage to inflammatory signaling because released IL-33 engages ST2-expressing immune cells and amplifies type 2 immune responses[1][1]. In asthma, alternative IL33 transcript splicing generates IL-33 isoforms that activate basophils and mast cells, supporting type 2 inflammation in chronic stable asthma[1]. Compared with full-length nuclear IL-33, the natural IL33Δ34 isoform lacks nuclear targeting, accumulates in the cytoplasm, and undergoes tonic apical secretion through exosome-associated trafficking in airway basal cells[2]. Therefore, isoform selection matters in IL-33 research because altered localization and secretion can change experimental readouts in airway disease models[1][2]. For inhibitor studies, anti-IL-33 antibodies such as tozorakimab neutralize IL-33red-ST2 signaling and prevent IL-33ox-associated RAGE/EGFR signaling, providing tools to test IL-33-dependent inflammation and epithelial dysfunction[3].

IL-33 Related Products (4):

Cat. No. Product Name Effect Purity
  • HY-P99444
    Astegolimab
    		Inhibitor 99.00%
    Astegolimab (MSTT 1041A; RG 6149) is a human IgG2 monoclonal antibody. Astegolimab blocks IL-33 signaling by targeting the IL-33 receptor ST2. Astegolimab reduces p53 expression, mitigates IL33-upregulated SASP factors such as IL1α, IL6 and MCP1. Astegolimab mitigates IL33-increased p-p65/p65 ratio. Astegolimab blocks CM-induced neutrophil extracellular trap (NET) formation. Astegolimab is used in chronic obstructive pulmonary disease (COPD) and myocardial research.
  • HY-W060417
    iST2-1
    		Inhibitor 99.58%
    iST2-1 is an Stimulation-2 (ST2) inhibitor with an IC50 value of 46.65 μM, blocks interaction between ST2 and IL-33, inhibits downstream signaling. iST2-1 functions as an immunomodulator, reduces proliferation of CD4+ and CD8+ T cells, increases regulatory T cell populations, reduces IFN-γ+CD4+ T cell populations, increases Foxp3+CD4+ regulatory T cell populations in the gastrointestinal tract. iST2-1 reduces plasma soluble ST2 and IFN-γ levels, reduces graft-versus-host disease scores, improves survival in graft-versus-host disease animal models, preserves graft-versus-tumor effect. iST2-1 can be used for the research of graft-versus-host disease.
  • HY-P991633
    TQC2938
    		Inhibitor
    TQC2938 is a humanized IgG2 monoclonal antibody inhibitor targeting Stimulation-2 (ST2). TQC2938 inhibits the ST2/IL-33 signaling pathway, reduces the level of downstream Th2 cytokines (such as IL-4, IL-5, and IL-13) and eosinophils as well as other inflammatory cells. TQC2938 can be used for inflammatory diseases like asthma research.
  • HY-P992440
    PF-06817024
    		Inhibitor
    PF-06817024 is a high affinity, humanized antibody that binds IL-33. PF-06817024 binds to IL-33, prevents IL-33 from binding to receptor ST2, and inhibits downstream type 2 inflammatory responses. PF-06817024 can be used for the research of allergic diseases.